EASL 2026 Reflections: Key takeaways in late-onset genetic cholestasis and Alagille syndrome
Dr Silvia Vilarinho and Dr Deepak Joshi reflect on the highlights from EASL Congress 2026, focusing on late‑onset genetic cholestasis and new insights in Alagille syndrome. They discuss the expanding role of genomic testing in adults, the move toward multidisciplinary Genetic Grand Rounds, and emerging IBAT‑targeted therapies and pregnancy data that are changing diagnosis and management.
Evolving therapeutic approaches in late-onset genetic cholestasis
Carola Dröge and Verena Keitel-Anselmino discuss IBAT inhibitor therapy in adults with hereditary BSEP-deficiency at EASL 2026.
Case series suggests IBAT inhibitor benefits in adults with hereditary BSEP deficiency
Clinical data suggest comparable IBAT inhibitor response for adults with hereditary BSEP deficiency as seen in pediatric trials.
Researchers call for ICP to be included in hepatobiliary risk stratification
Intrahepatic cholestasis of pregnancy significantly increases the risk for developing hepatobiliary morbidity.
Seladelpar improves wellbeing and lowers itch impact
Marlyn Mayo reviews RESPONSE analyses on seladelpar symptom effects in PBC.
Survey reveals limitations to pruritus assessment in PSC
Marlyn Mayo discusses findings on physician attitudes to managing pruritus in PSC.
Digital mind–body intervention helps symptom management in liver disease
A mind–body intervention accessed online may help patients with liver disease better manage their symptoms.
Gene mutations linked to adult cholestasis
Mitchell Shiffman discusses the value of genetic testing in adults with undefined cholestasis.
Long-term elafibranor therapy improves PBC outcomes
ELATIVE open-label extension trial findings support long-term elafibranor treatment in patients with PBC.
Distressing PSC symptoms fit profiles that could guide treatment
US researchers have found that the numerous and potentially distressing symptoms of PSC fit into four clear profiles.
Contraceptives linked to unique cholestatic phenotype
Raj Vuppalanchi reports findings characterizing the phenotype of women with hormonal contraceptive-associated drug-induced liver injury.
Elafibranor improves symptom burden, unaffected by BMI
Andreas Kremer discusses post-hoc analyses from the ELATIVE trial showing independent improvement in patient-reported outcomes with elafibranor for patients with PBC and efficacy irrespective of BMI.
IBAT inhibitor case studies point to adult intrahepatic cholestasis benefits
Ileal bile acid transporter inhibitors help treat adults with drug-induced or pregnancy-related intrahepatic cholestasis
Diagnosing and managing late-onset genetic cholestasis: a clinical pathway tool
A practical algorithm tool to help you navigate the different clinical presentations, reach an accurate diagnosis, and take optimal first management steps.
EASL guidelines offer ‘framework’ for intrahepatic cholestasis of pregnancy care
Research confirms that the EASL guidelines aid risk stratification for intrahepatic cholestasis of pregnancy.
Pathogenic variants common in adult-onset cholestasis patients
Research shows the utility of genetic testing for patients with adult-onset cholestatic disease.
Intrahepatic cholestasis of pregnancy EASL guidelines aid risk stratification
Ms Nina Rodriguez and Dr Tatyana Kushner confirm that the 2023 EASL guidelines can help risk stratify patients with intrahepatic cholestasis of pregnancy.
ABCB4 variant genotype–phenotype relationship in cholestasis elucidated
Research sheds light on the varying impact of ABCB4 gene variants in intrahepatic cholestasis of pregnancy and other adult-onset forms of cholestasis.
Odevixibat update for adult PFIC, older Alagille syndrome patients
Updated results for adult participants of the PEDFIC2 trial and older children taking part in the ASSERT-EXT study.
Genetic analysis aids diagnosis for atypical PFIC presentation
Case studies demonstrate the utility of genetic analysis and whole-exome sequencing for the diagnosis of progressive familial intrahepatic cholestasis in patients with nonspecific liver disease.
Comprehensive PBC management: innovative and personalized plans to enhance patient outcomes
Led by Emma Culver, this interactive case study follows a 40-year-old woman who is referred to the clinic following profound fatigue, and discusses how management plans can be personalized to best support patient outcomes.
PFIC trial updates continue to support IBAT inhibitor efficacy and safety
Professor Richard Thompson shares his PFIC poster findings on the long-term efficacy and safety data of the PEDFIC 2 trial and the relationship between serum bile acid and event-free survival in the MARCH and MARCH-ON trials.
Oral contraceptive absorption unhindered by odevixibat in healthy women
Trial findings suggest that the IBAT inhibitor odevixibat does not prevent absorption of combined oral contraceptives in healthy women.
Navigating Challenges in PBC Management: Focus on Inadequate Responders and Symptomatic Itching
In this case study module, Marlyn Mayo discusses 3 short patient profiles to illustrate difficult situations when treating patients with PBC including managing inadequate response to initial therapy and symptomatic itching.
PBC Clinical insights: evaluating therapeutic response and disease management
CME case study for the identification and management of Primary Biliary Cholangitis (PBC) including therapy response and disease management, for a 42 year old with abnormal liver blood test results.
Coping with PBC: treatment challenges and QoL insights
Kris Kowdley meets with patient Sabrina Reeser as they discuss the patient experience of treatment for PBC, including treatment challenges, variability in doctor-patient communication and involvement in clinical trials.
Walking the path of PBC: navigating symptoms and QoL
David Jones meets with patient and patient advocate Mo Christie as they discuss the patient experience for PBC, including the burden of the disease and its impact on quality of life, with special reference to the common, and commonly misunderstood symptom, itch.
Barriers and symptoms burden: the unmet needs in PBC
Drs Marlyn Mayo and Gideon Hirschfield discuss the unmet needs in PBC management, highlighting the significant burden that symptoms pose for patients, the importance of monitoring and a patient-centric management approach offering insights into what might lie ahead in 2024.
